Therefore, although the NRF2 pathway appears to play opposite roles in COVID-19 and lung cancer, targeting the NRF2 pathway by applying nanomaterial delivery systems can be a viable approach for lung cancer patients with COVID-19 symptoms. This evidence concerns the gene NFE2L2 and lung carcinoma.